MLKL-IN-6

MLKL-IN-6

• UNSPSC Description: MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects[1].
• Target Antigen: Mixed Lineage Kinase; Necroptosis
• Type: Reference compound
• Related Pathways: Apoptosis;MAPK/ERK Pathway
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Cancer; Metabolic Disease
• Assay Protocol: https://www.medchemexpress.com/mlkl-in-6.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(OC)/C=C/C(N1C)=NC(N(CC#CC2=CC=CC(O)=C2)C(N3C)=O)=C1C3=O
• Molecular Weight: 394.38
• References & Citations: [1]Oh J H, et al. Novel Inhibitor of Mixed-Lineage Kinase Domain-Like Protein: The Antifibrotic Effects of a Necroptosis Antagonist[J]. ACS Pharmacology & Translational Science, 2023.. . .
• Shipping Conditions: Room Temperature
• Clinical Information: No Development Reported